

ANASTROZOLE:

Class: Antineoplastic Agent, Aromatase Inhibitor

Indications: Advanced and early breast cancer

Available dosage form in the hospital: IMG TAB || 0.5%+NAPHAZOLINE 0.025% E/D

Trade Names: Anatrole (NZ); Anazo (TW); Anzol (PH); Aremed (TH, TW)

Dosage: Females: Postmenopausal:

-**Breast cancer, advanced:** Oral: 1 mg once daily; continue until tumor progression

-**Breast cancer, early (adjuvant treatment):** Oral: 1 mg once daily; optimal duration unknown, duration in clinical trial is 5 years.

Geriatric

Refer to adult dosing

Renal impairment:

Dosage adjustment is not necessary

Hepatic impairment:

-Mild-to-moderate impairment or stable hepatic cirrhosis: Dosage adjustment is not required.

-Severe hepatic impairment: Has not been studied in this population

Common side effect:

>10%:

Cardiovascular: Vasodilatation (25% to 36%), ischemic cardiovascular disease (4%; 17% in patients with pre-existing ischemic heart disease), hypertension (2% to 13%), angina (2%; 12% in patients with pre-existing ischemic heart disease)

Central nervous system: Mood disturbance (19%), fatigue (19%), pain (11% to 17%), headache (9% to 13%), depression (5% to 13%)

Dermatologic: Rash (6% to 11%)

Endocrine & metabolic: Hot flashes (12% to 36%)

Gastrointestinal: Nausea (11% to 19%), vomiting (8% to 13%)

Neuromuscular & skeletal: Weakness (16% to 19%), arthritis (17%), arthralgia (2% to 15%), back pain (10% to 12%), bone pain (6% to 11%), osteoporosis (11%)

Respiratory: Pharyngitis (6% to 14%), cough increased (8% to 11%)

1% to 10%:

Cardiovascular: Peripheral edema (5% to 10%), chest pain (5% to 7%), edema (7%), venous thromboembolic events (2% to 4%), ischemic cerebrovascular events (2%), MI (1%)

Central nervous system: Insomnia (2% to 10%), dizziness (6% to 8%), anxiety (2% to 6%), fever (2% to 5%), malaise (2% to 5%), confusion (2% to 5%), nervousness (2% to 5%), somnolence (2% to 5%), lethargy (1%)

Dermatologic: Alopecia (2% to 5%), pruritus (2% to 5%)

Endocrine & metabolic: Hypercholesterolemia (9%), breast pain (2% to 8%)

Gastrointestinal: Diarrhea (8% to 9%), constipation (7% to 9%), abdominal pain (7% to 9%), weight gain (2% to 9%), anorexia (5% to 7%), xerostomia (6%), dyspepsia (7%), weight loss (2% to 5%)

Genitourinary: Urinary tract infection (2% to 8%), vulvovaginitis (6%), pelvic pain (5%), vaginal bleeding (1% to 5%), vaginitis (4%), vaginal discharge (4%), vaginal hemorrhage (2% to 4%), leukorrhea (2% to 3%), vaginal dryness (2% to 5%)

Hematologic: Anemia (2% to 5%), leukopenia (2% to 5%)

Hepatic: Liver function tests increased (1% to 10%), alkaline phosphatase increased (1% to 10%), gamma GT increased ($\leq 5\%$)

Local: Thrombophlebitis (2% to 5%)

Neuromuscular & skeletal: Fracture (1% to 10%), arthrosis (7%), paresthesia (5% to 7%), joint disorder (6%), myalgia (2% to 6%), neck pain (2% to 5%), carpal tunnel syndrome (3%), hypertonia (3%)

Ocular: Cataracts (6%)

Respiratory: Dyspnea (8% to 10%), sinusitis (2% to 6%), bronchitis (2% to 5%), rhinitis (2% to 5%)

Miscellaneous: Lymphedema (10%), infection (2% to 9%), flu-like syndrome (2% to 7%), diaphoresis (2% to 5%), cyst (5%), neoplasm (5%), tumor flare (3%)

Pregnancy Risk Factor: X